AB0011 The estimation of synovial fluid immunological parameters in rheumatoid arthritis

Autor: GA Tsaur, VV Bazarniy, SV Tsvirenko, NS Petrovich

Publikováno v: Speaker abstracts 2001.

Background Objectives Laboratory synovial fluid (SF) tests are often held for joints condition, stage and acuteness of the inflammatory processes estimation. Immunological exams of SF is not routine procedure in clinical practice. We have studied the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::dc0fb8440178097e31650bfd61e15b08
https://doi.org/10.1136/annrheumdis-2001.810

[Minimal residual disease monitoring by flow cytometry in children with acute lymphoblastic leukemia]

Autor: Am, Popov, Verzhbitskaia TIu, Ga, Tsaur, Egor Shorikov, Li, Savel Ev, Sv, Tsvirenko, Lg, Fechina

Publikováno v: Europe PubMed Central

The cells that have avoided the action of antitumor drugs may be retained after remission achievement during induction therapy and consolidation. A combination of these cells is given the name minimal residual disease (MRD). Multicolor flow cytometry

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::b22c8dcdf42a50374eb0230fc59953b4
http://europepmc.org/abstract/med/20886718

[The limited possibility of using a simplified approach to detect minimal residual disease by the flow cytometry technique in children with precursor B-lineage acute lymphoblastic leukemia]

Autor: Am, Popov, Verzhbitskaia T, Ga, Tsaur, Egor Shorikov, Sv, Tsvirenko, Li, Savel Ev, Lg, Fechina

Publikováno v: Europe PubMed Central

Minimal residue disease (MRD) is a state in which the tumor cells remain in the patient in the amounts unrecognizable with the standard cytological techniques. Flow cytometry is one of the basic methods for evaluation of MRD in precursor B-lineage ac

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::6e00b36df5f560e67bb9eb02293b607b
http://europepmc.org/abstract/med/21574456

Exome, transcriptome and miRNA analysis don't reveal any molecular markers of TKI efficacy in primary CML patients.

Autor: Lavrov AV; Laboratory of Mutagenesis, Federal State Budgetary Institution, Research Centre for Medical Genetics, Moskvorechie str., 1, Moscow, Russian Federation, 115522. alexandervlavrov@gmail.com.; Department of Molecular and Cellular Genetics, State Budgetary Educational Institution of Higher Professional Education 'Russian National Research Medical University named after N.I. Pirogov' of Ministry of Health of the Russian Federation, Ostrovityanova str., 1, Moscow, Russian Federation, 117997. alexandervlavrov@gmail.com., Chelysheva EY; Scientific and Advisory Department of Chemotherapy of Myeloproliferative disorders, Federal State-Funded Institution National Research Center for Hematology of the Ministry of Healthcare of the Russian Federation, Novy Zykovki proezd, 4, Moscow, Russian Federation, 125167., Adilgereeva EP; Laboratory of Mutagenesis, Federal State Budgetary Institution, Research Centre for Medical Genetics, Moskvorechie str., 1, Moscow, Russian Federation, 115522., Shukhov OA; Scientific and Advisory Department of Chemotherapy of Myeloproliferative disorders, Federal State-Funded Institution National Research Center for Hematology of the Ministry of Healthcare of the Russian Federation, Novy Zykovki proezd, 4, Moscow, Russian Federation, 125167., Smirnikhina SA; Laboratory of Mutagenesis, Federal State Budgetary Institution, Research Centre for Medical Genetics, Moskvorechie str., 1, Moscow, Russian Federation, 115522., Kochergin-Nikitsky KS; Laboratory of Mutagenesis, Federal State Budgetary Institution, Research Centre for Medical Genetics, Moskvorechie str., 1, Moscow, Russian Federation, 115522., Yakushina VD; Laboratory of Mutagenesis, Federal State Budgetary Institution, Research Centre for Medical Genetics, Moskvorechie str., 1, Moscow, Russian Federation, 115522., Tsaur GA; Regional Children Hospital 1, S. Deryabinoy str., 32, Ekaterinburg, Russian Federation, 620149.; Research Institute of Medical Cell Technologies, Soboleva str., 25, Ekaterinburg, Russian Federation, 620905.; Federal State Budgetary Educational Institution of Higher Education, Urals State Medical University of the Ministry of Healthcare of the Russian Federation, Repina str., 3, Ekaterinburg, Russian Federation, 620028., Mordanov SV; Laboratory of Medical Genetics, The Rostov State Medical University, Nahichevansky av., 29, Rostov-on-Don, Russian Federation, 344022., Turkina AG; Scientific and Advisory Department of Chemotherapy of Myeloproliferative disorders, Federal State-Funded Institution National Research Center for Hematology of the Ministry of Healthcare of the Russian Federation, Novy Zykovki proezd, 4, Moscow, Russian Federation, 125167., Kutsev SI; Laboratory of Mutagenesis, Federal State Budgetary Institution, Research Centre for Medical Genetics, Moskvorechie str., 1, Moscow, Russian Federation, 115522.; Department of Molecular and Cellular Genetics, State Budgetary Educational Institution of Higher Professional Education 'Russian National Research Medical University named after N.I. Pirogov' of Ministry of Health of the Russian Federation, Ostrovityanova str., 1, Moscow, Russian Federation, 117997.

Publikováno v: BMC medical genomics [BMC Med Genomics] 2019 Mar 13; Vol. 12 (Suppl 2), pp. 37. Date of Electronic Publication: 2019 Mar 13.

[Biological microchip for establishing the structure of fusion transcripts involving MLL in children with acute leukemia].

Autor: Nasedkina TV; Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991 Russia.; Rogachev Federal Clinical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, 119117 Russia.; nased@eimb.ru., Ikonnikova AY; Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991 Russia., Tsaur GA; Regional Children's Clinical Hospital no. 1, Yekaterinburg, 620149 Russia.; Institute of Medical Cell Technologies, Yekaterinburg, 620026 Russia.; Yeltsin Ural Federal University, Yekaterinburg, 620002 Russia., Karateeva AV; Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991 Russia., Ammour YI; Rogachev Federal Clinical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, 119117 Russia., Avdonina MA; Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991 Russia., Karachunskii AI; Rogachev Federal Clinical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, 119117 Russia., Zasedatelev AS; Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991 Russia.

Publikováno v: Molekuliarnaia biologiia [Mol Biol (Mosk)] 2016 Nov-Dec; Vol. 50 (6), pp. 968-977.